A randomized single blind standard controlled study was conducted to evaluate the efficacy of Habbe Aftimoon in the patients of dyslipidemia with Atherosclerosis. Thirty diagnosed patients were selected and randomly allocated to Control and Test groups (comprising 20 patients in Test group and 10 in Control group). Habbe Aftimoon in a dose of 4 Habb twice a day in Test group whereas Lipotab 2 tablets once a day was given in Control group for 60 days. All the patients were advised low fatty diet and moderate exercise. Before and after the treatment, both groups were assessed on subjective and objective parameters. The outcome of treatment were analyzed statistically by using Paired ‘t’ test, Wilcoxon test, Friedman test with post test, one way ANOVA with post test and Kruskal Wallis test with Dunn’s multiple compare test.

The Test drugs exhibited statistically significant result in subjective parameters (Palpitation and Body weight) in intra group and inter group comparison. In objective parameters, reduction in S. Cholesterol and increase in L ank ASI and ABI were observed, and this difference was found statistically significant in intra group comparison. The control drug exhibited significant improvement in palpitation and reduces body weight in intra and inter group comparison. In objective parameters, S. Cholesterol and S. Triglyceride were significantly decreased in intra group comparison, where as the changes in other subjective and objective Parameters were remain insignificant in both groups.

The study revealed that Test drug is effective in some objective and subjective parameters in patients of dyslipidemia with Atherosclerosis particularly in reducing body weight and S. Cholesterol level. No adverse effect and toxicity was seen during and after the study. Thus, it can be concluded that Test drug is effective and safe in the management of Atherosclerosis in dyslipidemic patients up to some extent. So, it may be recommended for delaying complications of Atherosclerosis.